[DOI] [PMC free article] [PubMed] [Google Scholar] 11.Kabahizi A., Wallace B., Lieu L., Chau D., Dong Y., Hwang E.S., Williams K.W
GLP-1 drugs suppress the desire for food by influencing the neurons in the brains reward system
The Dulaglutide segment dominated the market with a share of 36.84% in 2025 due to its strong clinical efficacy, convenient once-weekly dosing schedule, proven cardiovascular benefits, and extensive physician adoption across diabetes treatment programs
I find that the announcement of the shortage led to a significant proliferation of companies, almost exclusively from China, that were marketing semaglutide in the U.S., with little indication that they are doing so in support of generic drug applications